BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia

The B-cell receptor (BCR) signaling inhibitors ibrutinib and idelalisib are revolutionizing the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. These oral agents, both alone and in combination with other drugs, have shown remarkable clinical activity in relapsed or ref...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mediterr J Hematol Infect Dis
Main Authors: Falchi, Lorenzo, Baron, Jessica M., Orlikowski, Carrie Anne, Ferrajoli, Alessandra
Format: Artigo
Sprog:Inglês
Udgivet: Università Cattolica del Sacro Cuore 2016
Fag:
Review Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4771137/
https://ncbi.nlm.nih.gov/pubmed/26977270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2016.011
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker